McNally R T, Brockbank K G
CryoLife, Inc. Marietta, Georgia 30067.
ASAIO Trans. 1991 Jul-Sep;37(3):M355-6.
This study analyzes the 5 year, clinical performance of 5,000 recorded implants of cryopreserved human heart valves. Successive changes in the processing methods have increased cell viability to 88% of control data. Data show that increased cell viability correlates with improved clinical performance. The 79 reported removals at 5 years gave an actuarial survival estimate for all reoperations and complications of 97%.
本研究分析了5000例冷冻保存的人心脏瓣膜植入物的5年临床性能。处理方法的相继改变已将细胞活力提高到对照数据的88%。数据表明,细胞活力的提高与临床性能的改善相关。报告的5年时79例移除病例得出所有再次手术和并发症的精算生存率估计为97%。